Hashemnia Seyyed Mohammad Reza, Meshkani Reza, Zamani-Garmsiri Fahimeh, Shabani Maryam, Tajabadi-Ebrahimi Maryam, Ragerdi Kashani Iraj, Siadat Seyed Davar, Mohassel Azadi Samaneh, Emamgholipour Solaleh
Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Department of Anatomy, School of Medicine, Tehran University of Medical Science, Tehran, Tehran, Iran.
Life Sci. 2023 Feb 1;314:121286. doi: 10.1016/j.lfs.2022.121286. Epub 2022 Dec 13.
Fresh evidence suggests that B. coagulans can be regarded as a promising therapeutic alternative for metabolic disorders. However, the possible effects of this probiotic on obesity-induced adipose tissue inflammation are unknown.
C57BL/6j male mice were assigned to a normal-chow diet (NCD) or a high-fat diet (HFD) for 10 weeks. After this period, HFD-fed mice were randomly divided into two groups; HFD control group and HFD plus B. coagulans T4 (IBRC-N10791) for another 8 weeks. B. coagulans T4 was administrated daily by oral intragastric gavage (1 × 10 colony-forming units).
Here, we found that B. coagulans successfully mitigated obesity and related metabolic disorder, as indicated by reduced body weight gain, decreased adiposity, and improved glucose tolerance. B. coagulans T4 administration also inhibited HFD-induced macrophage accumulation in white adipose tissue and switched M1 to M2 macrophages. In parallel, B. coagulans T4 treatment attenuated HFD-induced alteration in mRNA expression of pro/anti-inflammatory cytokines and Tlr4 in white adipose tissue. Moreover, B. coagulans T4 supplementation reduced the Firmicutes/Bacteriodetes ratio and increased the number of Lactobacillus and Faecalibacterium compared to the HFD group. Additionally, a significant increase in propionate and acetate levels in the HFD group was seen following B. coagulans T4 administration.
Taken together, the present study provides evidence that B. coagulans T4 supplementation exerts anti-obesity effects in part through attenuating inflammation in adipose tissue. The present study will have significant implications for obesity management.
新证据表明凝结芽孢杆菌可被视为代谢紊乱的一种有前景的治疗选择。然而,这种益生菌对肥胖诱导的脂肪组织炎症的可能影响尚不清楚。
将C57BL/6j雄性小鼠分为正常饲料饮食(NCD)组或高脂饮食(HFD)组,为期10周。在此期间后,高脂饮食喂养的小鼠随机分为两组;高脂饮食对照组和高脂饮食加凝结芽孢杆菌T4(IBRC-N10791)组,再持续8周。通过口服灌胃每日给予凝结芽孢杆菌T4(1×10个菌落形成单位)。
在此,我们发现凝结芽孢杆菌成功减轻了肥胖及相关代谢紊乱,表现为体重增加减少、肥胖程度降低和葡萄糖耐量改善。给予凝结芽孢杆菌T4还抑制了高脂饮食诱导的白色脂肪组织中巨噬细胞的积累,并使M1巨噬细胞转变为M2巨噬细胞。同时,凝结芽孢杆菌T4处理减弱了高脂饮食诱导的白色脂肪组织中促炎/抗炎细胞因子和Tlr4 mRNA表达的改变。此外,与高脂饮食组相比,补充凝结芽孢杆菌T4降低了厚壁菌门/拟杆菌门的比例,并增加了乳酸杆菌和粪杆菌的数量。另外,给予凝结芽孢杆菌T4后,高脂饮食组的丙酸和乙酸水平显著升高。
综上所述,本研究提供了证据表明补充凝结芽孢杆菌T4部分通过减轻脂肪组织炎症发挥抗肥胖作用。本研究将对肥胖管理具有重要意义。